{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:22:10Z","timestamp":1791055330441,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-025-01555-4","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:43:51Z","timestamp":1740545031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer\u2019s disease in type 2 diabetes"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-8219","authenticated-orcid":false,"given":"Prakash","family":"Ramakrishan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6367-0365","authenticated-orcid":false,"given":"Jayaraman","family":"Rajangam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9636-8983","authenticated-orcid":false,"given":"Shaheedha Shabudeen","family":"Mahinoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-766X","authenticated-orcid":false,"given":"Shradha","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3977-1876","authenticated-orcid":false,"given":"Sabareesh","family":"Mekala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-0426","authenticated-orcid":false,"given":"Dinesh Kumar","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9863-4452","authenticated-orcid":false,"given":"Viswas Raja","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7143-0791","authenticated-orcid":false,"given":"Govindaraj","family":"Sabarees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-4848","authenticated-orcid":false,"given":"Ranakishor","family":"Pelluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"1555_CR1","doi-asserted-by":"publisher","unstructured":"Adem MA, Decourt B, Sabbagh MN (2024) Pharmacological approaches using diabetic drugs repurposed for Alzheimer\u2019s disease. Biomedicines 12(1):99. https:\/\/doi.org\/10.3390\/biomedicines12010099","DOI":"10.3390\/biomedicines12010099"},{"key":"1555_CR2","doi-asserted-by":"publisher","unstructured":"Ajoolabady A, Lindholm D, Ren J, Pratico D (2022) ER stress and UPR in Alzheimer\u2019s disease: mechanisms, pathogenesis, treatments. Cell Death Dis 13(8). https:\/\/doi.org\/10.1038\/s41419-022-05153-5","DOI":"10.1038\/s41419-022-05153-5"},{"issue":"4","key":"1555_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","volume":"12","author":"HH Arab","year":"2021","unstructured":"Arab HH, Safar MM, Shahin NN (2021) Targeting ROS-Dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by Dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model. ACS Chem Neurosci 12(4):689\u2013703. https:\/\/doi.org\/10.1021\/acschemneuro.0c00722","journal-title":"ACS Chem Neurosci"},{"key":"1555_CR4","doi-asserted-by":"publisher","unstructured":"Ardanaz CG, Ram\u00edrez MJ, Solas M (2022) Brain metabolic alterations in Alzheimer\u2019s disease. Int J Mol Sci 23(7). https:\/\/doi.org\/10.3390\/ijms23073785","DOI":"10.3390\/ijms23073785"},{"issue":"1","key":"1555_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","volume":"136","author":"WA Banks","year":"2012","unstructured":"Banks WA, Owen JB, Erickson MA (2012) Insulin in the brain: there and back again. Pharmacol Ther 136(1):82\u201393. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.07.006","journal-title":"Pharmacol Ther"},{"issue":"16","key":"1555_CR6","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2021.4001","volume":"325","author":"C Barbiellini Amidei","year":"2021","unstructured":"Barbiellini Amidei C, Fayosse A, Dumurgier J et al (2021) Association between age at diabetes onset and subsequent risk of Dementia. JAMA - J Am Med Assoc 325(16):1640\u20131649. https:\/\/doi.org\/10.1001\/jama.2021.4001","journal-title":"JAMA - J Am Med Assoc"},{"key":"1555_CR7","doi-asserted-by":"publisher","unstructured":"Barone E, Di Domenico F, Perluigi M, Butterfield DA (2021) The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radic Biol Med 17616\u201317633. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.09.006","DOI":"10.1016\/j.freeradbiomed.2021.09.006"},{"issue":"4","key":"1555_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/0891988710383571","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Review article: genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23(4):213\u2013227. https:\/\/doi.org\/10.1177\/0891988710383571","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1555_CR9","doi-asserted-by":"publisher","unstructured":"Beurel E, Grieco SF, Jope RS (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 148114\u2013148131. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.11.016","DOI":"10.1016\/j.pharmthera.2014.11.016"},{"issue":"2","key":"1555_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F et al (2022) Two Randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"1555_CR11","doi-asserted-by":"publisher","unstructured":"Cai Z, Chen G, He W et al (2015) Activation of mTOR: a culprit of Alzheimer\u2019s disease? Neuropsychiatr Dis Treat 111015\u2013111030. https:\/\/doi.org\/10.2147\/NDT.S75717","DOI":"10.2147\/NDT.S75717"},{"key":"1555_CR12","doi-asserted-by":"publisher","unstructured":"Cefalo CMA, Cinti F, Moffa S et al (2019) Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol 18(1). https:\/\/doi.org\/10.1186\/s12933-019-0828-y","DOI":"10.1186\/s12933-019-0828-y"},{"issue":"5","key":"1555_CR13","doi-asserted-by":"publisher","first-page":"N112","DOI":"10.1016\/0968-0004(77)90168-2","volume":"2","author":"B Chance","year":"1977","unstructured":"Chance B (1977) The mechanism of oxidative phosphorylation. Trends Biochem Sci 2(5):N112\u2013N114. https:\/\/doi.org\/10.1016\/0968-0004(77)90168-2","journal-title":"Trends Biochem Sci"},{"key":"1555_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12929-020-00648-9","volume":"27","author":"YH Chang","year":"2020","unstructured":"Chang YH, Weng CL, Lin KI (2020) O-GlcNAcylation and its role in the immune system. J Biomed Sci 27:57. https:\/\/doi.org\/10.1186\/s12929-020-00648-9","journal-title":"J Biomed Sci"},{"issue":"4","key":"1555_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.amjms.2016.01.011","volume":"351","author":"R Chen","year":"2016","unstructured":"Chen R, Ovbiagele B, Feng W (2016) Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci 351(4):380\u2013386. https:\/\/doi.org\/10.1016\/j.amjms.2016.01.011","journal-title":"Am J Med Sci"},{"key":"1555_CR16","doi-asserted-by":"publisher","unstructured":"Courtney CH, Olefsky JM (2007) Insulin resistance. Mech Insul Action Med Intell Unit 185\u2013209. https:\/\/doi.org\/10.1007\/978-0-387-72204-7_10","DOI":"10.1007\/978-0-387-72204-7_10"},{"issue":"4","key":"1555_CR17","doi-asserted-by":"publisher","first-page":"e14463","DOI":"10.1111\/cns.14463","volume":"30","author":"S Davoody","year":"2024","unstructured":"Davoody S, Asgari Taei A, Khodabakhsh P, Dargahi L (2024) mTOR signaling and Alzheimer\u2019s disease: what we know and where we are? CNS Neurosci Ther 30(4):e14463. https:\/\/doi.org\/10.1111\/cns.14463","journal-title":"CNS Neurosci Ther"},{"key":"1555_CR18","doi-asserted-by":"publisher","unstructured":"de la Monte SM (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer\u2019s disease. Curr Alzheimer Res 9(1):35\u201366. https:\/\/doi.org\/10.2174\/15672051279901503","DOI":"10.2174\/15672051279901503"},{"key":"1555_CR19","unstructured":"De Meyts P (2000) The insulin receptor and its signal transduction network. Endotext.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/27512793\/"},{"issue":"1","key":"1555_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA Deture","year":"2019","unstructured":"Deture MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14(1):1\u201318. https:\/\/doi.org\/10.1186\/s13024-019-0333-5","journal-title":"Mol Neurodegener"},{"issue":"14","key":"1555_CR21","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.3390\/ijms22147644","volume":"22","author":"L Dilworth","year":"2021","unstructured":"Dilworth L, Facey A, Omoruyi F (2021) Diabetes mellitus and its metabolic complications: the role of adipose tissues. Int J Mol Sci 22(14):7644. https:\/\/doi.org\/10.3390\/ijms22147644","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1555_CR22","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/alz.12482","volume":"17","author":"A Dove","year":"2021","unstructured":"Dove A, Shang Y, Xu W, Grande G, Laukka EJ, Fratiglioni L, Marseglia A (2021) The impact of diabetes on cognitive impairment and its progression to dementia. Alzheimers Dement 17(11):1769\u20131778. https:\/\/doi.org\/10.1002\/alz.12482","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1555_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH et al (2016) Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimer\u2019s Dement 12(3):292\u2013323. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.002","journal-title":"Alzheimer\u2019s Dement"},{"key":"1555_CR24","doi-asserted-by":"publisher","unstructured":"Erdogan MA, Yusuf D, Christy J et al (2018) Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurol 18(1). https:\/\/doi.org\/10.1186\/s12883-018-1086-4","DOI":"10.1186\/s12883-018-1086-4"},{"key":"1555_CR25","doi-asserted-by":"publisher","unstructured":"Femminella GD, Livingston NR, Raza S et al (2021) Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer\u2019s subjects? Alzheimer\u2019s Res Ther 13(1). https:\/\/doi.org\/10.1186\/s13195-021-00784-w","DOI":"10.1186\/s13195-021-00784-w"},{"key":"1555_CR26","doi-asserted-by":"publisher","unstructured":"Finkbeiner S (2020) The autophagy lysosomal pathway and neurodegeneration. Cold Spring Harb Perspect Biol 12(3). https:\/\/doi.org\/10.1101\/cshperspect.a033993","DOI":"10.1101\/cshperspect.a033993"},{"issue":"2","key":"1555_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27(2):136\u2013142. https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02894.x","journal-title":"Diabet Med"},{"issue":"1","key":"1555_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22(1):1\u201337. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"issue":"23","key":"1555_CR29","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"C-X Gong","year":"2008","unstructured":"Gong C-X, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15(23):2321\u20132328. https:\/\/doi.org\/10.2174\/092986708785909111","journal-title":"Curr Med Chem"},{"issue":"1","key":"1555_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-022-00996-8","volume":"14","author":"A Gonz\u00e1lez","year":"2022","unstructured":"Gonz\u00e1lez A, Calf\u00edo C, Churruca M, Maccioni RB (2022) Glucose metabolism and AD: evidence for a potential diabetes type 3. Alzheimer\u2019s Res Ther 14(1):1\u201311. https:\/\/doi.org\/10.1186\/s13195-022-00996-8","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1555_CR31","doi-asserted-by":"publisher","unstructured":"Goschorska M, Gutowska I, Baranowska-Bosiacka I et al (2019) Influence of acetylcholinesterase inhibitors used in alzheimer\u2019s disease treatment on the activity of antioxidant enzymes and the concentration of glutathione in THP-1 macrophages under fluoride-induced oxidative stress. Int J Environ Res Public Health 16(1). https:\/\/doi.org\/10.3390\/ijerph16010010","DOI":"10.3390\/ijerph16010010"},{"issue":"8","key":"1555_CR32","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s00125-017-4285-4","volume":"60","author":"SM Gray","year":"2017","unstructured":"Gray SM, Aylor KW, Barrett EJ (2017) Unravelling the regulation of insulin transport across the brain endothelial cell. Diabetologia 60(8):1512\u20131521. https:\/\/doi.org\/10.1007\/s00125-017-4285-4","journal-title":"Diabetologia"},{"issue":"3","key":"1555_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13300-024-01538-1","volume":"15","author":"PY Gunawan","year":"2024","unstructured":"Gunawan PY, Gunawan PA, Hariyanto TI (2024) Risk of dementia in patients with diabetes using sodium-glucose transporter 2 inhibitors (SGLT2i): a systematic review, Meta-analysis, and Meta-Regression. Diabetes Ther 15(3):663\u2013675. https:\/\/doi.org\/10.1007\/s13300-024-01538-1","journal-title":"Diabetes Ther"},{"issue":"1","key":"1555_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01251-0","volume":"7","author":"J Guo","year":"2022","unstructured":"Guo J, Huang X, Dou L et al (2022) Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther 7(1):1\u201340. https:\/\/doi.org\/10.1038\/s41392-022-01251-0","journal-title":"Signal Transduct Target Ther"},{"key":"1555_CR35","doi-asserted-by":"publisher","unstructured":"Hasan I, Rashid T, Jaikaransingh V, Heilig C, Abdel-Rahman EM, Awad AS (2024) SGLT2 inhibitors: beyond glycemic control. J Clin Transl Endocrinol 35:100335. ISSN 2214\u20136237.\u00a0https:\/\/doi.org\/10.1016\/j.jcte.2024.100335","DOI":"10.1016\/j.jcte.2024.100335"},{"key":"1555_CR36","doi-asserted-by":"publisher","unstructured":"Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, Alves-Martinez P, Lubian-Lopez S, Garcia-Alloza M (2020) Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes. Alzheimers Res Ther 12(1):40. https:\/\/doi.org\/10.1186\/s13195-020-00607-4","DOI":"10.1186\/s13195-020-00607-4"},{"key":"1555_CR37","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2147\/CIA.S429440","volume":"2","author":"SJ Hou","year":"2023","unstructured":"Hou SJ, Zhang SX, Li Y, Xu SY (2023) Rapamycin responds to Alzheimer\u2019s disease: a potential translational therapy. Clin Interv Aging 2:18:1629\u20131639. https:\/\/doi.org\/10.2147\/CIA.S429440","journal-title":"Clin Interv Aging"},{"issue":"1","key":"1555_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT (2017) An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 24(1):73\u201379. https:\/\/doi.org\/10.1097\/MED.0000000000000311","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1555_CR39","unstructured":"IDF (2021) IDF Diabetes Atlas 2021 _ IDF Diabetes Atlas. In: IDF Off. website"},{"key":"1555_CR40","doi-asserted-by":"publisher","unstructured":"Kim B, Elzinga SE, Henn RE et al (2019a) The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer\u2019s disease. Neurobiol Dis 132104541. https:\/\/doi.org\/10.1016\/j.nbd.2019.104541","DOI":"10.1016\/j.nbd.2019.104541"},{"key":"1555_CR41","first-page":"107899","volume":"158","author":"Y Kim","year":"2019","unstructured":"Kim Y et al (2019b) SGLT2 inhibitors and neuroprotection in cognitive decline. Diabetes Res Clin Pract 158:107899","journal-title":"Diabetes Res Clin Pract"},{"key":"1555_CR42","doi-asserted-by":"publisher","unstructured":"Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11(1):2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","DOI":"10.1038\/s41467-020-15983-6"},{"issue":"7","key":"1555_CR43","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.3949\/ccjm.84.s1.03","volume":"84","author":"JP Kirwan","year":"2017","unstructured":"Kirwan JP, Sacks J, Nieuwoudt S (2017) The essential role of exercise in the management of type 2 diabetes. Cleve Clin J Med 84(7):S15\u2013S21. https:\/\/doi.org\/10.3949\/ccjm.84.s1.03","journal-title":"Cleve Clin J Med"},{"key":"1555_CR44","doi-asserted-by":"publisher","unstructured":"Klen, Jasna, Dol\u017ean V (2021) Treatment response to SGLT2 inhibitors: from clinical characteristics to genetic variations. Int J Molec Sci 22(18):9800. https:\/\/doi.org\/10.3390\/ijms22189800","DOI":"10.3390\/ijms22189800"},{"issue":"7","key":"1555_CR45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3390\/ijms20071591","volume":"20","author":"X Kou","year":"2019","unstructured":"Kou X, Chen D, Chen N (2019) Physical activity alleviates cognitive dysfunction of alzheimer\u2019s disease through regulating the mtor signaling pathway. Int J Mol Sci 20(7):1591. https:\/\/doi.org\/10.3390\/ijms20071591","journal-title":"Int J Mol Sci"},{"key":"1555_CR46","doi-asserted-by":"publisher","unstructured":"Kumar V, Kim SH, Bishayee K (2022) Dysfunctional glucose metabolism in Alzheimer\u2019s disease onset and potential pharmacological interventions. Int J Mol Sci 23(17). https:\/\/doi.org\/10.3390\/ijms23179540","DOI":"10.3390\/ijms23179540"},{"issue":"4","key":"1555_CR47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2174\/1573403x15666190730094215","volume":"16","author":"G Kyriakos","year":"2019","unstructured":"Kyriakos G, Quiles-Sanchez LV, Garmpi A et al (2019) SGLT2 inhibitors and Cardiovascular outcomes: do they differ or there is a class Effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study. Curr Cardiol Rev 16(4):258\u2013265. https:\/\/doi.org\/10.2174\/1573403x15666190730094215","journal-title":"Curr Cardiol Rev"},{"issue":"8","key":"1555_CR48","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3390\/biomedicines12081750","volume":"12","author":"A Lardaro","year":"2024","unstructured":"Lardaro A, Quarta L, Pagnotta S, Sodero G, Mariani S, Del Ben M, Desideri G, Ettorre E, Baratta F (2024) Impact of Sodium glucose cotransporter 2 inhibitors (SGLT2i) therapy on Dementia and Cognitive decline. Biomedicines 12(8):1750. https:\/\/doi.org\/10.3390\/biomedicines12081750","journal-title":"Biomedicines"},{"key":"1555_CR49","doi-asserted-by":"publisher","unstructured":"Lim L (2024) Modifying Alzheimer\u2019s disease pathophysiology with photobiomodulation: model, evidence, and future with EEG-guided intervention. Front Neurol 151407785. https:\/\/doi.org\/10.3389\/fneur.2024.1407785","DOI":"10.3389\/fneur.2024.1407785"},{"key":"1555_CR50","unstructured":"Liman MNP, Jialal I (2020) Physiology, glycosuria. StatPearls"},{"issue":"8","key":"1555_CR51","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1038\/s41380-022-01600-z","volume":"27","author":"P Liu","year":"2022","unstructured":"Liu P, Wang ZH, Kang SS, Liu X, Xia Y, Chan CB, Ye K (2022) High-fat diet-induced diabetes couples to Alzheimer\u2019s disease through inflammation-activated C\/EBP\u03b2\/AEP pathway. Mol Psychiatry 27(8):3396\u20133409. https:\/\/doi.org\/10.1038\/s41380-022-01600-z","journal-title":"Mol Psychiatry"},{"issue":"10248","key":"1555_CR52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396(10248):413\u2013446. https:\/\/doi.org\/10.1016\/S0140-6736(20)30367-6","journal-title":"Lancet"},{"key":"1555_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3233\/jad-215678","volume":"87","author":"S Low","year":"2022","unstructured":"Low S, Goh KS, Ng TP, Moh A, Ang SF, Wang J et al (2022) Association between use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and cognitive function in a longitudinal study of patients with type 2 diabetes. J Alzheimers Dis 87:635\u2013642. https:\/\/doi.org\/10.3233\/jad-215678","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1555_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-024-00431-y","volume":"13","author":"J Mei","year":"2024","unstructured":"Mei J, Li Y, Niu L et al (2024) SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system. Transl Neurodegener 13(1):1\u201316. https:\/\/doi.org\/10.1186\/s40035-024-00431-y","journal-title":"Transl Neurodegener"},{"issue":"10","key":"1555_CR55","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","volume":"36","author":"P Mergenthaler","year":"2013","unstructured":"Mergenthaler P, Lindauer U, Dienel GA, Meisel A (2013) Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36(10):587\u2013597. https:\/\/doi.org\/10.1016\/j.tins.2013.07.001","journal-title":"Trends Neurosci"},{"issue":"3","key":"1555_CR56","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/ijms15034671","volume":"15","author":"A Mietelska-Porowska","year":"2014","unstructured":"Mietelska-Porowska A, Wasik U, Goras M et al (2014) Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci 15(3):4671\u20134713. https:\/\/doi.org\/10.3390\/ijms15034671","journal-title":"Int J Mol Sci"},{"key":"1555_CR57","doi-asserted-by":"publisher","unstructured":"Miranda M, Morici JF, Zanoni MB, Bekinschtein P (2019) Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci 13. https:\/\/doi.org\/10.3389\/fncel.2019.00363","DOI":"10.3389\/fncel.2019.00363"},{"key":"1555_CR58","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2337\/dc21-2434","volume":"45","author":"P Mone","year":"2022","unstructured":"Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M et al (2022) Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 45:1247\u20131251. https:\/\/doi.org\/10.2337\/dc21-2434","journal-title":"Diabetes Care"},{"key":"1555_CR59","doi-asserted-by":"publisher","unstructured":"Mui JV, Zhou J, Lee S, Leung KSK, Lee TTL, Chou OHI, Tsang SL, Wai AKC, Liu T, Wong WT, Chang C, Tse G, Zhang Q (2021) Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) inhibitors for New-Onset Dementia: a propensity score-matched Population-based study with competing risk analysis. Front Cardiovasc Med 21:8:747620. https:\/\/doi.org\/10.3389\/fcvm.2021.747620","DOI":"10.3389\/fcvm.2021.747620"},{"key":"1555_CR60","doi-asserted-by":"publisher","unstructured":"Nguyen TT, Ta QTH, Nguyen TKO et al (2020) Type 3 diabetes and its role implications in alzheimer\u2019s disease. Int J Mol Sci 21(9). https:\/\/doi.org\/10.3390\/ijms21093165","DOI":"10.3390\/ijms21093165"},{"issue":"2","key":"1555_CR61","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E, Steinmetz JD, Vollset SE et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of Disease Study 2019. Lancet Public Heal 7(2):e105\u2013e125. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8","journal-title":"Lancet Public Heal"},{"issue":"1","key":"1555_CR62","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/biom5010194","volume":"5","author":"K Nowotny","year":"2015","unstructured":"Nowotny K, Jung T, H\u00f6hn A et al (2015) Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5(1):194\u2013222. https:\/\/doi.org\/10.3390\/biom5010194","journal-title":"Biomolecules"},{"key":"1555_CR63","unstructured":"Padda IS, Mahtani AU, Parmar M (2022) Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. StatPearls"},{"issue":"5","key":"1555_CR64","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/13543776.2019.1612879","volume":"29","author":"J Pandey","year":"2019","unstructured":"Pandey J, Tamrakar AK (2019) SGLT2 inhibitors for the treatment of diabetes: a patent review (2013\u20132018). Expert Opin Ther Pat 29(5):369\u2013384. https:\/\/doi.org\/10.1080\/13543776.2019.1612879","journal-title":"Expert Opin Ther Pat"},{"key":"1555_CR65","doi-asserted-by":"publisher","unstructured":"Pawlos A, Broncel M, Wo\u017aniak E, Gorzelak-Pabi\u015b P (2021) Neuroprotective effect of SGLT2 inhibitors. Molecules 26(23):7213. https:\/\/doi.org\/10.3390\/molecules26237213","DOI":"10.3390\/molecules26237213"},{"key":"1555_CR66","doi-asserted-by":"publisher","unstructured":"Peng Y, Jin H, Xue YH et al (2023) Current and future therapeutic strategies for Alzheimer\u2019s disease: an overview of drug development bottlenecks. Front Aging Neurosci 151206572. https:\/\/doi.org\/10.3389\/fnagi.2023.1206572","DOI":"10.3389\/fnagi.2023.1206572"},{"key":"1555_CR67","doi-asserted-by":"publisher","unstructured":"Perluigi M, Di Domenico F, Barone E, Butterfield DA (2021) mTOR in Alzheimer disease and its earlier stages: links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med 169382\u2013169396. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.04.025","DOI":"10.1016\/j.freeradbiomed.2021.04.025"},{"issue":"4","key":"1555_CR68","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","volume":"98","author":"MC Petersen","year":"2018","unstructured":"Petersen MC, Shulman GI (2018) Mechanisms of insulin action and insulin resistance. Physiol Rev 98(4):2133\u20132223. https:\/\/doi.org\/10.1152\/physrev.00063.2017","journal-title":"Physiol Rev"},{"issue":"4","key":"1555_CR69","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00213-023-06341-7","volume":"240","author":"I Pi\u0105tkowska-Chmiel","year":"2023","unstructured":"Pi\u0105tkowska-Chmiel I, Herbet M, Gawro\u0144ska-Grzywacz M, Paw\u0142owski K, Ostrowska-Le\u015bko M, Dudka J (2023) Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology 240(4):983\u20131000. https:\/\/doi.org\/10.1007\/s00213-023-06341-7","journal-title":"Psychopharmacology"},{"key":"1555_CR70","doi-asserted-by":"publisher","unstructured":"Pungsrinont T, Kallenbach J, Baniahmad A (2021) Role of pi3k-akt-mtor pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci 22(20). https:\/\/doi.org\/10.3390\/ijms222011088","DOI":"10.3390\/ijms222011088"},{"issue":"4","key":"1555_CR71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s43657-023-00098-x","volume":"3","author":"M Quan","year":"2023","unstructured":"Quan M, Cao S, Wang Q et al (2023) Genetic phenotypes of Alzheimer\u2019s disease: mechanisms and potential therapy. Phenomics 3(4):333\u2013349. https:\/\/doi.org\/10.1007\/s43657-023-00098-x","journal-title":"Phenomics"},{"issue":"21","key":"1555_CR72","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"25","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH (2022) Phosphorylated tau in Alzheimer\u2019s Disease and other tauopathies. Int J Mol Sci 25(21):12841. https:\/\/doi.org\/10.3390\/ijms232112841","journal-title":"Int J Mol Sci"},{"key":"1555_CR73","doi-asserted-by":"publisher","first-page":"105330","DOI":"10.1016\/j.neubiorev.2023.105330","volume":"153","author":"JM Rethelyi","year":"2023","unstructured":"Rethelyi JM, Vincze K, Schall D, Glennon J, Berkel S (2023) The role of insulin\/IGF1 signalling in neurodevelopmental and neuropsychiatric disorders - evidence from human neuronal cell models. Neurosci Biobehav Rev 153:105330. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105330","journal-title":"Neurosci Biobehav Rev"},{"key":"1555_CR74","first-page":"833234","volume":"13","author":"MR Rizzo","year":"2022","unstructured":"Rizzo MR et al (2022) Cognitive effects of SGLT2 inhibitors in non-diabetic individuals: emerging insights. Front Endocrinol 13:833234","journal-title":"Front Endocrinol"},{"issue":"3","key":"1555_CR75","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11011-020-00663-7","volume":"36","author":"P Sa-Nguanmoo","year":"2021","unstructured":"Sa-Nguanmoo P et al (2021) The neuroprotective effects of SGLT2 inhibitors: focus on cognitive decline in metabolic disorders. Metab Brain Dis 36(3):421\u2013432","journal-title":"Metab Brain Dis"},{"key":"1555_CR76","unstructured":"Sam C, Bordoni B (2021) Physiology, acetylcholine. StatPearls"},{"issue":"4","key":"1555_CR77","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/jdi.13255","volume":"11","author":"R Sano","year":"2020","unstructured":"Sano R, Shinozaki Y, Ohta T (2020) Sodium\u2013glucose cotransporters: functional properties and pharmaceutical potential. J Diabetes Investig 11(4):770\u2013782. https:\/\/doi.org\/10.1111\/jdi.13255","journal-title":"J Diabetes Investig"},{"issue":"1","key":"1555_CR78","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPKRASRAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):103\u2013119. https:\/\/doi.org\/10.1517\/14728222.2011.645805","journal-title":"Expert Opin Ther Targets"},{"key":"1555_CR79","doi-asserted-by":"publisher","first-page":"666958","DOI":"10.3389\/fnins.2021.666958","volume":"16","author":"AM Saunders","year":"2021","unstructured":"Saunders AM, Burns DK, Gottschalk WK (2021) Reassessment of pioglitazone for Alzheimer\u2019s disease. Front Neurosci 16:15:666958. https:\/\/doi.org\/10.3389\/fnins.2021.666958","journal-title":"Front Neurosci"},{"issue":"2","key":"1555_CR80","first-page":"101235","volume":"48","author":"S Saussez","year":"2022","unstructured":"Saussez S et al (2022) SGLT2 inhibitors reduce ER stress and improve metabolic health: implications for mTORsignaling. Diabetes Metab 48(2):101235","journal-title":"Diabetes Metab"},{"issue":"6","key":"1555_CR81","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168(6):960\u2013976. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"issue":"1","key":"1555_CR82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/febs.12590","volume":"281","author":"S Schedin-Weiss","year":"2014","unstructured":"Schedin-Weiss S, Winblad B, Tjernberg LO (2014) The role of protein glycosylation in Alzheimer disease. FEBS J 281(1):46\u201362. https:\/\/doi.org\/10.1111\/febs.12590","journal-title":"FEBS J"},{"key":"1555_CR83","doi-asserted-by":"publisher","unstructured":"Schultz C (2012) Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective. Ophthalmol Eye Dis 4OED.S7383. https:\/\/doi.org\/10.4137\/oed.s7383","DOI":"10.4137\/oed.s7383"},{"key":"1555_CR84","doi-asserted-by":"publisher","unstructured":"Scisciola L, Cataldo V, Taktaz F et al (2022) Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med 9. https:\/\/doi.org\/10.3389\/fcvm.2022.1008922","DOI":"10.3389\/fcvm.2022.1008922"},{"issue":"2","key":"1555_CR85","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.molcel.2010.09.026","volume":"40","author":"S Sengupta","year":"2010","unstructured":"Sengupta S, Peterson TR, Sabatini DM (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40(2):310\u2013322. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.026","journal-title":"Mol Cell"},{"issue":"14","key":"1555_CR86","doi-asserted-by":"publisher","first-page":"11497","DOI":"10.3390\/ijms241411497","volume":"24","author":"F Shi","year":"2023","unstructured":"Shi F, Collins S (2023) Regulation of mTOR signaling: emerging role of cyclic nucleotide-dependent protein kinases and implications for Cardiometabolic Disease. Int J Mol Sci 24(14):11497. https:\/\/doi.org\/10.3390\/ijms241411497","journal-title":"Int J Mol Sci"},{"key":"1555_CR87","doi-asserted-by":"crossref","unstructured":"Sim AY, Barua S, Kim JY, Lee YH, Lee JE (2021) Role of DPP-4 and SGLT2 inhibitors connected to Alzheimer disease in type 2 diabetes mellitus. Front Neurosci 15:708547","DOI":"10.3389\/fnins.2021.708547"},{"issue":"6","key":"1555_CR88","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S2213-8587(20)30118-2","volume":"8","author":"V Srikanth","year":"2020","unstructured":"Srikanth V, Sinclair AJ, Hill-Briggs F et al (2020) Type 2 diabetes and cognitive dysfunction\u2014towards effective management of both comorbidities. Lancet Diabetes Endocrinol 8(6):535\u2013545. https:\/\/doi.org\/10.1016\/S2213-8587(20)30118-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1555_CR89","doi-asserted-by":"publisher","unstructured":"Stanciu GD, Rusu RN, Bild V et al (2021) Systemic actions of sglt2 inhibition on chronic mtor activation as a shared pathogenic mechanism between Alzheimer\u2019s disease and diabetes. Biomedicines 9(5). https:\/\/doi.org\/10.3390\/biomedicines9050576","DOI":"10.3390\/biomedicines9050576"},{"key":"1555_CR90","doi-asserted-by":"publisher","unstructured":"Tamagno E, Guglielmotto M, Vasciaveo V, Tabaton M (2021) Oxidative stress and beta amyloid in Alzheimer\u2019s disease. Which comes first: chick or egg? Antioxid 10(9). https:\/\/doi.org\/10.3390\/antiox10091479","DOI":"10.3390\/antiox10091479"},{"key":"1555_CR91","doi-asserted-by":"publisher","unstructured":"Tan VP, Miyamoto S (2016) Nutrient-sensing mTORC1: integration of metabolic and autophagic signals. J Mol Cell Cardiol 9531\u20139541. https:\/\/doi.org\/10.1016\/j.yjmcc.2016.01.005","DOI":"10.1016\/j.yjmcc.2016.01.005"},{"issue":"7","key":"1555_CR92","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbamcr.2015.03.003","volume":"1853","author":"Z Tang","year":"2015","unstructured":"Tang Z, Ioja E, Bereczki E et al (2015) MTor mediates tau localization and secretion: implication for Alzheimer\u2019s disease. Biochim Biophys Acta - Mol Cell Res 1853(7):1646\u20131657. https:\/\/doi.org\/10.1016\/j.bbamcr.2015.03.003","journal-title":"Biochim Biophys Acta - Mol Cell Res"},{"issue":"8","key":"1555_CR93","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1002\/alz.14048","volume":"20","author":"H Tang","year":"2024","unstructured":"Tang H, Donahoo WT, Svensson M et al (2024) Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: a population-based cohort study. Alzheimer\u2019s Dement 20(8):5528\u20135539. https:\/\/doi.org\/10.1002\/alz.14048","journal-title":"Alzheimer\u2019s Dement"},{"key":"1555_CR94","doi-asserted-by":"publisher","unstructured":"Taoufik E, Kouroupi G, Zygogianni O, Matsas R (2018) Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models. Open Biol 8(9). https:\/\/doi.org\/10.1098\/rsob.180138","DOI":"10.1098\/rsob.180138"},{"key":"1555_CR95","doi-asserted-by":"publisher","unstructured":"Tcw J, Goate AM (2017) Genetics of \u03b2-Amyloid precursor protein in Alzheimer\u2019s disease. Cold Spring Harb Perspect Med 7(6). https:\/\/doi.org\/10.1101\/cshperspect.a024539","DOI":"10.1101\/cshperspect.a024539"},{"key":"1555_CR96","doi-asserted-by":"publisher","unstructured":"Tharmaraja T, Ho JSY, Sia CH et al (2022) Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Ther Adv Chronic Dis 13. https:\/\/doi.org\/10.1177\/20406223221086996","DOI":"10.1177\/20406223221086996"},{"issue":"10367","key":"1555_CR97","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(22)02480-1","volume":"400","author":"The Lancet","year":"2022","unstructured":"The Lancet (2022) Lecanemab for Alzheimer\u2019s disease: tempering hype and hope. Lancet 400(10367):1899. https:\/\/doi.org\/10.1016\/S0140-6736(22)02480-1","journal-title":"Lancet"},{"key":"1555_CR98","doi-asserted-by":"publisher","unstructured":"Umegaki H (2014) Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin Interv Aging 91011\u201391019. https:\/\/doi.org\/10.2147\/CIA.S48926","DOI":"10.2147\/CIA.S48926"},{"key":"1555_CR99","doi-asserted-by":"publisher","unstructured":"Vallon V, Verma S (2021) Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 83503\u201383528. https:\/\/doi.org\/10.1146\/annurev-physiol-031620-095920","DOI":"10.1146\/annurev-physiol-031620-095920"},{"key":"1555_CR100","doi-asserted-by":"publisher","unstructured":"Wici\u0144ski M, W\u00f3dkiewicz E, G\u00f3rski K et al (2020) Perspective of sglt2 inhibition in treatment of conditions connected to neuronal loss: Focus on Alzheimer\u2019s disease and ischemia-related brain injury. Pharmaceuticals 13(11):1\u201312. https:\/\/doi.org\/10.3390\/ph13110379","DOI":"10.3390\/ph13110379"},{"key":"1555_CR101","doi-asserted-by":"publisher","unstructured":"Xie PL, Zheng MY, Han R et al (2024) Pharmacological mTOR inhibitors in ameliorating Alzheimer\u2019s disease: current review and perspectives. Front Pharmacol 151366061. https:\/\/doi.org\/10.3389\/fphar.2024.1366061","DOI":"10.3389\/fphar.2024.1366061"},{"issue":"4","key":"1555_CR102","doi-asserted-by":"publisher","first-page":"45844","DOI":"10.1136\/bmjopen-2020-045844","volume":"11","author":"D Yabe","year":"2021","unstructured":"Yabe D, Shiki K, Suzaki K et al (2021) Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet. BMJ Open 11(4):45844. https:\/\/doi.org\/10.1136\/bmjopen-2020-045844","journal-title":"BMJ Open"},{"key":"1555_CR103","doi-asserted-by":"publisher","unstructured":"Yang L, Zhang X, Wang Q (2022) Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front Endocrinol (Lausanne) 13. https:\/\/doi.org\/10.3389\/fendo.2022.992937","DOI":"10.3389\/fendo.2022.992937"},{"key":"1555_CR104","doi-asserted-by":"publisher","unstructured":"Youssef ME, Yahya G, Popoviciu MS et al (2023) Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Mol Sci 24(7):6039. https:\/\/doi.org\/10.3390\/ijms24076039","DOI":"10.3390\/ijms24076039"},{"key":"1555_CR105","doi-asserted-by":"publisher","unstructured":"Zhang H, Ma Q, Zhang YW, Xu H (2012) Proteolytic processing of Alzheimer\u2019s \u03b2-amyloid precursor protein. J Neurochem 120(SUPPL. 1):9\u201321. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07519.x","DOI":"10.1111\/j.1471-4159.2011.07519.x"},{"key":"1555_CR106","doi-asserted-by":"publisher","unstructured":"Zhang J, Chen C, Hua S et al (2017) An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer\u2019s disease. Diabetes Res Clin Pract 12441\u201312447. https:\/\/doi.org\/10.1016\/j.diabres.2016.10.024","DOI":"10.1016\/j.diabres.2016.10.024"},{"key":"1555_CR107","unstructured":"Zhang X et al (2021) Environmental determinants of drug efficacy in chronic diseases.\u00a0J Clin Pharmacol"},{"issue":"1","key":"1555_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-024-01325-9","volume":"16","author":"R Zhang","year":"2024","unstructured":"Zhang R, Xie Q, Lu X et al (2024) Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndr 16(1):1\u201315. https:\/\/doi.org\/10.1186\/s13098-024-01325-9","journal-title":"Diabetol Metab Syndr"},{"key":"1555_CR109","doi-asserted-by":"publisher","unstructured":"Zhu BT (2022) Pathogenic mechanism of autoimmune diabetes mellitus in humans: potential role of streptozotocin-induced selective autoimmunity against human islet \u03b2-Cells. Cells 11(3). https:\/\/doi.org\/10.3390\/cells11030492","DOI":"10.3390\/cells11030492"},{"key":"1555_CR110","doi-asserted-by":"publisher","unstructured":"Z\u0142otek M, Kurowska A, Herbet M, Pi\u0105tkowska-Chmiel I (2023) GLP-1 analogs, SGLT-2, and DPP-4 inhibitors: a triad of hope for Alzheimer\u2019s disease therapy. Biomedicines 11(11):3035. https:\/\/doi.org\/10.3390\/biomedicines11113035","DOI":"10.3390\/biomedicines11113035"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-025-01555-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T15:32:20Z","timestamp":1743089540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-025-01555-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":110,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1007\/s11011-025-01555-4","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}